This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adinoff, A. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adinoff, A. D.

PEDIATRICS Vol. 104 No. 2 Supplement August 1999, pp. 366

Urticaria and Angioedema
Angioneurotic Edema Attributed to the Use of Losartan

van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J Arch Intern Med. 1998; 158:2063-2065 [Medline]

The first 20% of the full text of this article appears below.

Purpose of the Study Angioedema is a well-known adverse effect of angiotensin-converting enzyme inhibitors. The bradykinin accumulation as a result of the decreased degradation of bradykinin is thought to be the causal mechanism. Angiotensin II antagonists seem to have no effect on the degradation of bradykinin. Therefore, it was expected that angioedema would not occur during treatment with losartan potassium, the first orally active angiotensin II antagonist.

Study Population and . . . [Full Text of this Article]